Left ventricular ejection fraction determined with the simulation of a very low-dose CZT-SPECT protocol and an additional count-calibration on planar radionuclide angiographic data.
Adult
Aged
Angiography
Antineoplastic Agents
/ therapeutic use
Cadmium
Calibration
Cardiomyopathies
/ diagnostic imaging
Computer Simulation
Erythrocytes
/ drug effects
Female
Gamma Cameras
Heart Ventricles
/ diagnostic imaging
Humans
Male
Middle Aged
Neoplasms
/ diagnostic imaging
Prospective Studies
Radionuclide Angiography
Stroke Volume
Tellurium
Tomography, Emission-Computed, Single-Photon
Ventricular Function, Left
Zinc
Blood-pool SPECT
CZT-camera
Calibration curve
Left ventricular ejection fraction
Radionuclide angiography
Journal
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
29
10
2018
accepted:
21
12
2018
pubmed:
1
3
2019
medline:
21
10
2020
entrez:
1
3
2019
Statut:
ppublish
Résumé
To determine whether the left ventricular ejection fractions (EFs), measured on a high-sensitivity CZT single photon emission computed tomography (SPECT)-camera with a 70% reduction in recording times and a prevention of EF overestimation through an additional count-calibration, are concordant with reference EF from planar radionuclide angiography (2D-RNA). An additional 10-minute CZT-SPECT recording was performed in patients referred to 2D-RNA for cardiomyopathy (n = 23) or chemotherapy monitoring (n = 50) with an in vivo red blood cell labeling with 850 MBq [Formula: see text]. The EF, obtained from CZT-SPECT with 100% (SPECT100) or 30% (SPECT30) projection times and with a SPECT-count calibration on the 2D-RNA counts of corresponding cavity volumes, were compared to EF from 2D-RNA. Strong and equivalent relationships were documented between the EF from 2D-RNA and the calibrated EF from SPECT100 (y = 0.89x + 6.62; R Left ventricular EF may be determined on a high-sensitivity CZT-camera, a 70% reduction in injected activities, and an additional count-calibration for further enhancing the concordance with 2D-RNA values.
Identifiants
pubmed: 30815836
doi: 10.1007/s12350-019-01619-w
pii: 10.1007/s12350-019-01619-w
doi:
Substances chimiques
Antineoplastic Agents
0
CdZnTe
0
Cadmium
00BH33GNGH
Zinc
J41CSQ7QDS
Tellurium
NQA0O090ZJ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1539-1549Commentaires et corrections
Type : CommentIn
Références
J Nucl Cardiol. 2018 Dec;25(6):2016-2023
pubmed: 28512723
Clin Physiol Funct Imaging. 2015 Nov;35(6):418-24
pubmed: 24980073
J Nucl Cardiol. 2010 Jun;17(3):427-34
pubmed: 20151236
Ann Nucl Med. 2008 Apr;22(3):171-6
pubmed: 18498031
Curr Cardiol Rep. 2017 Apr;19(4):31
pubmed: 28315122
J Nucl Cardiol. 1999 Sep-Oct;6(5):498-506
pubmed: 10548145
J Nucl Cardiol. 2018 Aug 17;:null
pubmed: 30120749
J Nucl Cardiol. 2016 Jun;23(3):348-61
pubmed: 26956876
Ann Oncol. 2012 Oct;23 Suppl 7:vii155-66
pubmed: 22997448
J Nucl Cardiol. 2014 Apr;21(2):384-96
pubmed: 24366823
Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):851-85
pubmed: 18224320
J Nucl Med. 1996 Nov;37(11):1795-9
pubmed: 8917177
Eur J Nucl Med Mol Imaging. 2013 Aug;40(8):1163-70
pubmed: 23632963
J Nucl Med. 2012 Apr;53(4):584-91
pubmed: 22393224
Br J Radiol. 2008 Apr;81(964):270-4
pubmed: 18250120
J Nucl Cardiol. 2011 Aug;18(4):642-9
pubmed: 21647809
Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):522-8
pubmed: 24202049
J Nucl Med. 2016 Sep;57(9):1370-5
pubmed: 27127220
Nucl Med Commun. 2005 Apr;26(4):351-9
pubmed: 15753795
J Nucl Med. 2012 Dec;53(12):1897-903
pubmed: 23139084
Ann ICRP. 2013 Feb;42(1):1-125
pubmed: 23141687
J Nucl Cardiol. 2005 Jan-Feb;12(1):78-85
pubmed: 15682368
J Nucl Cardiol. 2016 Oct;23(5):1128-1138
pubmed: 26231888
J Nucl Cardiol. 2007 Jul;14(4):544-9
pubmed: 17679063
Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1004-11
pubmed: 25711177
J Nucl Cardiol. 2018 Feb;25(1):249-256
pubmed: 27677613